Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low‐dose total body irradiation, and rabbit antithymocyte globulin
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Transplantation"
DOI: 10.1111/ctr.14018
Abstract: Optimal conditioning and graft‐vs‐host disease (GVHD) prophylaxis for hematopoietic cell transplantation (HCT) are unknown. Here, we report on outcomes after low toxicity, myeloablative conditioning consisting of fludarabine, busulfan, and 4 Gy total body irradiation, in… read more here.
Keywords: total body; conditioning; body irradiation; hematopoietic cell ... See more keywords
Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active.
Sign Up to like & getrecommendations! Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2021005566
Abstract: Adding the selective BCL-2 inhibitor venetoclax to reduced intensity conditioning (RIC) chemotherapy (fludarabine and busulfan, FluBu2) may enhance anti-leukemic cytotoxicity and thereby reduce the risk of post-transplant relapse. This phase 1 study investigated the recommended… read more here.
Keywords: risk; high risk; transplant; fludarabine busulfan ... See more keywords
Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e19520
Abstract: e19520Background: Scoring systems, such as DIPSS-plus, prognosticate outcomes of myelofibrosis (MF) at diagnosis and at transplant. In this study, we evaluated the impact of individual components o... read more here.
Keywords: myeloablative fludarabine; long term; fludarabine busulfan; regimen myelofibrosis ... See more keywords
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Sign Up to like & getrecommendations! Published in 2023 at "Haematologica"
DOI: 10.3324/haematol.2022.281958
Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, the optimal conditioning regimen either with reduced intensity conditioning (RIC) or myeloablative conditioning (MAC) is not well known. Using the Center for… read more here.
Keywords: allogeneic hematopoietic; fludarabine busulfan; hematopoietic cell; myelofibrosis ... See more keywords